Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Novel CD123xCD3 Bispecific Igm Antibody, Igm-2537, Potently Induces T-Cell Mediated Cytotoxicity of Acute Myeloid Leukemia Cells In Vivo and in Vitro with Minimal Cytokine Release

Blood (2023) 142 (Supplement 1): 4177.

https://doi.org/10.1182/blood-2023-182891

Published: 2023

Journal Articles

CD123 Directed IgM Antibody-based T-cell Engager, IGM-2537, Demonstrates Potent in vitro and in vivo Activity with Minimal Cytokine Release

Liqin Liu, Gene Li, Ling Wang, Poonam Yakkundi, Paul R. Hinton, Deepal Pandya, Manal Amoury, Keerthana Sekar, Chian Liu, Rodnie Rosete, Nardeen Hanna, Maya F. Kotturi, Liz Bogaert, Jiyoung Hong, Christina Tsai, Bruce A. Keyt, Angus M. Sinclair

Blood (2022) 140 (Supplement 1): 5918–5919.

https://doi.org/10.1182/blood-2022-165817

Published: 2022

Journal Articles

Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile

Keyu Li, Rui Yun, Min Chai, Poonam Yakkundi, Rodnie Rosete, Gene Li, Liqin Liu, Dean Ng, Paul R. Hinton, Maya F. Kotturi, Angus M. Sinclair, Stephen F. Carroll, Umesh Muchhal, Bruce A. Keyt

Blood (2022) 140 (Supplement 1): 6010–6011.

https://doi.org/10.1182/blood-2022-159205

Published: 2022

Journal Articles

The Anti-Tumor Activity of Igm-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, Is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML

Beatrice T. Wang, PhD, Thomas J. Matthew, PhD, Ling Wang, MS, Tasnim Kothambawala, Susan E. Calhoun, MS, Eric W. Humke, MD, Angus M. Sinclair, PhD, Bruce A. Keyt, PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-141449

Published: 2020

Journal Articles

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Kimberly H. Harrington, BS, Chelsea J. Gudgeon, BS, George S. Laszlo, PhD, Kathryn J. Newhall, PhD, Angus M. Sinclair, PhD, Stanley R. Frankel, MD, Roman Kischel, MD, Guang Chen, PhD, Roland B. Walter, MD PhD MS

Blood (2014) 124 (21): 266.

https://doi.org/10.1182/blood.V124.21.266.266

Published: 2014

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 3738.

https://doi.org/10.1182/blood.V124.21.3738.3738

Published: 2014

Journal Articles

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

George S. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington, Justine Dell’Aringa, Kathryn J. Newhall, Gary D. Means, Angus M. Sinclair, Roman Kischel, Stanley R. Frankel, Roland B. Walter

Blood (2014) 123 (4): 554–561.

https://doi.org/10.1182/blood-2013-09-527044

Published: 2014

Includes: Supplemental data

Journal Articles

Absence of functional EpoR expression in human tumor cell lines

Susan Swift, Aaron R. Ellison, Paul Kassner, Ian McCaffery, John Rossi, Angus M. Sinclair, C. Glenn Begley, Steven Elliott

Blood (2010) 115 (21): 4254–4263.

https://doi.org/10.1182/blood-2009-10-248674

Published: 2010

Includes: Supplemental data

Journal Articles

Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells

Angus M. Sinclair, Angela Coxon, Ian McCaffery, Stephen Kaufman, Katherine Paweletz, Liqin Liu, Leigh Busse, Susan Swift, Steven Elliott, C. Glenn Begley

Blood (2010) 115 (21): 4264–4272.

https://doi.org/10.1182/blood-2009-10-248666

Published: 2010

Includes: Supplemental data

Journal Articles

Anti-Epo receptor antibodies do not predict Epo receptor expression

Steve Elliott, Leigh Busse, Michael B. Bass, Hsieng Lu, Ildiko Sarosi, Angus M. Sinclair, Chris Spahr, Moonkyoung Um, Gwyneth Van, C. Glenn Begley

Blood (2006) 107 (5): 1892–1895.

https://doi.org/10.1182/blood-2005-10-4066

Published: 2006

Includes: Supplemental data

Journal Articles

Is EPO Receptor Expressed in Human Tumor Cells?.

Angus M. Sinclair, Leigh Busse, Norma Rogers, Ildiko Sarosi, Gwyneth Van, Steve Elliott

Blood (2004) 104 (11): 3723.

https://doi.org/10.1182/blood.V104.11.3723.3723

Published: 2004

Journal Articles

Rescue of the lethal scl −/− phenotype by the human SCL locus

Angus M. Sinclair, Anthony J. Bench, Adrian J. C. Bloor, Juan Li, Berthold Göttgens, Maureen L. Stanley, Jane Miller, Sandie Piltz, Susie Hunter, Elisabeth P. Nacheva, Marı́a-José Sanchez, Anthony R. Green

Blood (2002) 99 (11): 3931–3938.

https://doi.org/10.1182/blood.V99.11.3931

Published: 2002

Journal Articles

Lymphoid apoptosis and myeloid hyperplasia in CCAAT displacement protein mutant mice

Angus M. Sinclair, Jamie A. Lee, Adrian Goldstein, Dongxia Xing, Shengxi Liu, Ruzeng Ju, Philip W. Tucker, Ellis J. Neufeld, Richard H. Scheuermann

Blood (2001) 98 (13): 3658–3667.

https://doi.org/10.1182/blood.V98.13.3658

Published: 2001

NARROW

Novel CD123xCD3 Bispecific Igm Antibody, Igm-2537, Potently Induces T-Cell Mediated Cytotoxicity of Acute Myeloid Leukemia Cells In Vivo and in Vitro with Minimal Cytokine Release

CD123 Directed IgM Antibody-based T-cell Engager, IGM-2537, Demonstrates Potent in vitro and in vivo Activity with Minimal Cytokine Release

Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile

The Anti-Tumor Activity of Igm-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, Is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

Absence of functional EpoR expression in human tumor cell lines

Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells

Anti-Epo receptor antibodies do not predict Epo receptor expression

Is EPO Receptor Expressed in Human Tumor Cells?.

Rescue of the lethal scl −/− phenotype by the human SCL locus

Lymphoid apoptosis and myeloid hyperplasia in CCAAT displacement protein mutant mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only